Myriad Genetics, NCCHE collaborate on SCRUM-MONSTAR-SCREEN-3 study

Myriad Genetics announced a research collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of molecular residual disease testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA over time in patients diagnosed with a wide array of solid tumor and hematological cancers. The SCRUM-MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino of the NCCHE, will explore how multi-omic profiling can be used to develop more personalized treatment and therapeutic strategies in three study cohorts. Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD. The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.